Ensysce Biosciences Bolsters Management Team with Appointments of David J. Kovacs as VP Public Policy and David Tanzer as VP Strategic Development
July 26 2021 - 8:00AM
Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ:
ENSC, OTC: ENSCW), a clinical-stage biotech company with
proprietary technology platforms to reduce the economic and social
burden of prescription drug abuse and overdose, has appointed David
J. Kovacs to the new position of VP Public Policy and David Tanzer
to the new position of VP Strategic Development, both effective
July 22, 2021.
Kovacs has extensive experience shaping policy and setting
strategy for disruptive companies in pharmaceutical and technology
sectors. Kovacs joins Ensysce from his prior role as Head of Public
Policy for Humanigen, Inc. (NASDAQ: HGEN), whose monoclonal
antibody lenzilumab recently requested Emergency Use Authorization
for the treatment of patients hospitalized with COVID-19. Kovacs
currently serves in various roles for public companies, including
Vinco Ventures (NASDAQ: BBIG) and AudioEye, Inc. (NASDAQ: AEYE).
Previously, Kovacs held senior roles in private equity and
investment banking, including at Blackstone Group, Citigroup, and
the Hinduja Group.
Tanzer is an accomplished business executive specializing in
helping companies with innovative intellectual property and
technology maximize their potential. Tanzer has 25 years of diverse
experience in the healthcare and media sectors, including as CEO or
President of eight companies, service on nine company boards, and
working at private equity firms, including Lee Equity Partners and
Elevation Partners. Tanzer previously was President of PDR Network,
publisher of the Physicians’ Desk Reference, the authoritative
source of drug safety information for prescribers.
Ensysce CEO Dr. Lynn Kirkpatrick commented: “I’m pleased to
welcome David Kovacs and David Tanzer to our leadership team, as
they bring significant capabilities and expertise that will advance
our strategy across multiple disciplines for our ‘next-generation’
opioids products alongside those for ADHD and Opioid Use Disorder.
We look forward to their contributions as we accelerate our
strategy to bring our lead products through registration.”
Kovacs commented: “I recently had the privilege to play an
important role in Humanigen’s life-saving COVID-19 therapeutic,
Lenzilumab, a critical tool to help society save lives and recover
from the pandemic. Now, I am excited to work with Ensysce to
accelerate the funding, development and commercialization of its
novel products to help address the opioid epidemic.”
Tanzer commented: “Ensysce has developed unique platforms to
curb abuse and overdose of prescription drugs, and their specific
focus on the opioid scourge is a timely response to a dire crisis
that has touched all of our lives.”
Dr. Kirkpatrick concluded: “Our successful merger with LACQ has
reinforced Ensysce’s position as a leader in the pain field and
provided us with a stronger foundation as we move our products
forward to provide novel options for both prescribers and
patients.”
Forward-Looking StatementsThis press release
contains certain forward-looking statements within the meaning of
federal securities laws. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this communication. Such factors can
be found in Ensysce’s most recent annual report on Form 10-K,
subsequently filed quarterly reports on Form 10-Q and current
reports on Form 8-K, which are available, free of charge, at the
SEC’s website at www.sec.gov, and also in the Form S-4 and
Ensysce’s definitive proxy statement/prospectus filed on June 16,
2021. New risks and uncertainties arise from time to time, and it
is impossible for us to predict these events or how they may affect
the Company. You are cautioned not to place undue reliance upon any
forward-looking statements, which speak only as of the date made,
and Ensysce undertakes no obligation to update or revise the
forward-looking statements, whether as a result of new information,
changes in expectations, future events or otherwise.
About Ensysce Biosciences (NASDAQ: ENSC)Ensysce
Biosciences, San Diego, CA is a clinical-stage biotech company
using its proprietary technology platforms to develop safer
prescription drugs. Leveraging its Trypsin Activated Abuse
Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR™)
platforms, the Company is developing a new class of powerful,
tamper-proof opioids that prevent both drug abuse and overdoses.
Ensysce’s products are anticipated to provide safer options to
treat severe pain and assist in preventing deaths caused by opioid
abuse, reducing the human and economic cost. The platforms are
covered by an extensive worldwide intellectual property portfolio
for a wide array of prescription drug compositions. For more
information, please visit www.ensysce.com.
Investor Relations Contact:Gateway Investor
RelationsMatt Glover, Alex Thompson(949)
574-3860Ensysce@gatewayir.com
Leisure Acquisition (NASDAQ:LACQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Leisure Acquisition (NASDAQ:LACQ)
Historical Stock Chart
From Sep 2023 to Sep 2024